| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 504 | 2017 |
| MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells GV Kryukov, FH Wilson, JR Ruth, J Paulk, A Tsherniak, SE Marlow, ... Science 351 (6278), 1214-1218, 2016 | 464 | 2016 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease F Van Rhee, P Voorhees, A Dispenzieri, A Fosså, G Srkalovic, M Ide, ... Blood, The Journal of the American Society of Hematology 132 (20), 2115-2124, 2018 | 324 | 2018 |
| Idiopathic multicentric Castleman's disease: a systematic literature review AY Liu, CS Nabel, BS Finkelman, JR Ruth, R Kurzrock, F van Rhee, ... The Lancet Haematology 3 (4), e163-e175, 2016 | 294 | 2016 |
| Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments MA LaBarge, CM Nelson, R Villadsen, A Fridriksdottir, JR Ruth, ... Integrative biology 1 (1), 70-79, 2009 | 214 | 2009 |
| Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy JV Alvarez, T Pan, J Ruth, Y Feng, A Zhou, D Pant, JS Grimley, ... Cancer cell 24 (1), 30-44, 2013 | 143 | 2013 |
| Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease DC Fajgenbaum, RA Langan, AS Japp, HL Partridge, SK Pierson, ... The Journal of clinical investigation 129 (10), 4451-4463, 2019 | 106 | 2019 |
| Cross-regulatory role of interferon-gamma (IFN-γ), IL-4 and IL-10 in schistosome egg granuloma formation: in vivo regulation of Th activity and inflammation SW Chensue, KS Warmington, J Ruth, PM Lincoln, SL Kunkel Clinical & Experimental Immunology 98 (3), 395-400, 1994 | 88 | 1994 |
| Non-invasive tissue temperature measurements based on quantitative diffuse optical spectroscopy (DOS) of water SH Chung, AE Cerussi, SI Merritt, J Ruth, BJ Tromberg Physics in Medicine & Biology 55 (13), 3753, 2010 | 75 | 2010 |
| Plasma proteomics identifies a ‘chemokine storm’in idiopathic multicentric Castleman disease SK Pierson, AJ Stonestrom, D Shilling, J Ruth, CS Nabel, A Singh, Y Ren, ... American journal of hematology 93 (7), 902-912, 2018 | 73 | 2018 |
| SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling Y Feng, TC Pan, DK Pant, KR Chakrabarti, JV Alvarez, JR Ruth, ... Cancer discovery 4 (7), 790-803, 2014 | 52 | 2014 |
| The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research DC Fajgenbaum, JR Ruth, D Kelleher, AH Rubenstein The Lancet Haematology 3 (4), e150-e152, 2016 | 46 | 2016 |
| Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease CS Nabel, S Sameroff, D Shilling, D Alapat, JR Ruth, M Kawano, Y Sato, ... PLoS One 14 (6), e0218660, 2019 | 36 | 2019 |
| Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease SK Pierson, S Shenoy, AB Oromendia, AM Gorzewski, RA Langan Pai, ... Blood advances 5 (17), 3445-3456, 2021 | 30 | 2021 |
| ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder SK Pierson, JS Khor, J Ziglar, A Liu, K Floess, E NaPier, AM Gorzewski, ... Cell Reports Medicine 1 (9), 2020 | 25 | 2020 |
| Cellular dormancy in minimal residual disease following targeted therapy JR Ruth, DK Pant, T Pan, HE Seidel, SC Baksh, BA Keister, R Singh, ... Breast Cancer Research 23 (1), 63, 2021 | 18 | 2021 |
| HHV-8-Negative, idiopathic multicentric Castleman disease (iMCD): a description of clinical features and therapeutic options through a systematic literature review DC Fajgenbaum, A Liu, J Ruth, C Nabel, B Finkelman, R Kurzrock, ... Blood 124 (21), 4861, 2014 | 15 | 2014 |
| Taking control of castleman disease: Leveraging precision medicine technologies to accelerate rare disease research SK Newman, RK Jayanthan, GW Mitchell, JA Carreras Tartak, MP Croglio, ... The Yale Journal of Biology and Medicine, 2015 | 11 | 2015 |
| Quantification of plasma proteins from idiopathic multicentric Castleman disease flares and remissions reveals ‘chemokine storm’and separates clinical subtypes SK Pierson, AJ Stonestrom, JR Ruth, D Shilling, H Li, Y Ren, K Stone, ... Blood 130, 3592, 2017 | 8 | 2017 |
| Crossregulatory role of-IFN, IL-4, and IL-10 in schistosome egg granuloma formation: in vivo regulation of Th activity and inflammation SW Chensue, KS Warmington, J Ruth, PM Lincoln, SL Kunkel Clin Exp Immunol 98, 395-400, 1994 | 5 | 1994 |
